Akari Therapeutics Plc (AKTX) Social Stream



Akari Therapeutics Plc (AKTX): $1.52

0.04 (+2.70%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add AKTX to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#441 of 496

in industry

AKARI THERAPEUTICS PLC (AKTX) Price Targets From Analysts

Use the tables below to see what analysts covering AKARI THERAPEUTICS PLC think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-11-01 1 $4 $4 $4 $2.89 38.41%
2022-12-05 1 $80 $30 $55 $2.89 1803.11%
NA 1 $NA $NA $NA $2.89 NA%

Price Target Last Issued NA NA, NA

500 - Internal server error

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential

AKTX Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 1 0 0 0 0 1

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • AKARI THERAPEUTICS PLC's number of analysts covering the stock is higher than just about none of of all US stocks.
  • AKTX has a lower variance in analysts' estimates than -71.24% of all US stocks.
  • To contextualize these metrics, consider that out of stocks in the micro market cap category, AKARI THERAPEUTICS PLC's average analyst price target is higher than 214.36% of them.
  • In terms of how AKARI THERAPEUTICS PLC fares relative to Pharmaceutical Products stocks, note that its upside potential (average analyst target price relative to current price) is higher than 222.89% of that group.

Stocks similar to AKARI THERAPEUTICS PLC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are PTN, HEPA, and PHIO.

Is AKTX a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!